About OliX Pharma
We are developing new therapeutic entities for treatment of diseases in skin, eye, or lung which are able to be accessed by local administration. We have a platform technology for cell penetrating asymmetric siRNA (cp-asiRNA) which can be efficiently internalized into cell and can specifically knock-down target gene expression without help of any delivery vehicle such as liposome or polymer. The most advanced program is OLX101 for hypertrophic scar for which there is no approved therapy. The IND of OLX101 was approved in Korean FDA in this January and clinical trial will be finished by the end of this year. We are also planning clinical study in Europe which will be started in October.
OLX201 program is for idiopathic pulmonary fibrosis (IPF), a rare, debilitating, and fatal disorder in which the lungs become progressively scarred over time. Our anti-scar molecule showed a great therapeutic efficacy in preclinical study, therefore we expect to start clinical trial in US in mid 2018. OLX301A for age-related macular degeneration (AMD) is a prominent first-in class drug that can treat both wet and dry types. The clinical trial is planned to start in US in early 2018.
Our anti-fibrosis molecule is being developed for wet AMD and retinal fibrosis, a common complication of wet AMD, in OLX301D program, of which clinical trial will be started in Europe in 2018.
State of Ownership
Business Development Executive, Nature Publishing Group, Springer Nature